LOCUS       sequence-96049-e         974 bp    DNA     linear   UNA 15-DEC-2025
DEFINITION  Expresses murine IFITM1-C83A with an N-terminal HA tag in mammalian 
            cells..
ACCESSION   .
VERSION     .
KEYWORDS    .
SOURCE      natural DNA sequence
  ORGANISM  unspecified
REFERENCE   1  (bases 1 to 974)
  AUTHORS   Hach JC, McMichael T, Chesarino NM, Yount JS
  TITLE     Palmitoylation on conserved and nonconserved cysteines of murine 
            IFITM1 regulates its stability and anti-influenza A virus activity.
  JOURNAL   J Virol. 2013 Sep;87(17):9923-7. doi: 10.1128/JVI.00621-13. Epub 
            2013 Jun 26.
  PUBMED    23804635
REFERENCE   2  (bases 1 to 974)
  AUTHORS   .
  TITLE     Direct Submission
  JOURNAL   Exported Dec 15, 2025 from SnapGene Server 8.0.1
            https://www.snapgene.com
COMMENT     SGRef: number: 1; type: "Journal Article"; doi: 
            "10.1128/JVI.00621-13"; journalName: "J Virol"; date: "2013-09"; 
            volume: "87"; issue: "17"; pages: "9923-7"
COMMENT     Sequence Label: pCMV-HA-mIFITM1-C83A
FEATURES             Location/Qualifiers
     source          1..974
                     /mol_type="genomic DNA"
                     /organism="unspecified"
     CDS             complement(395..421)
                     /codon_start=1
                     /product="HA (human influenza hemagglutinin) epitope tag"
                     /label=HA
                     /translation="YPYDVPDYA"
     intron          485..581
                     /label=SV40 intron
                     /note="modified SV40 intron with splice donor and acceptor 
                     sites"
     primer_bind     complement(698..722)
                     /label=LNCX
                     /note="Human CMV promoter, forward primer"
     promoter        complement(719..922)
                     /label=CMV promoter
                     /note="human cytomegalovirus (CMV) immediate early 
                     promoter"
     primer_bind     complement(748..768)
                     /label=CMV-F
                     /note="Human CMV immediate early promoter, forward primer"
ORIGIN
        1 tgtctggatc cccgcggccg cggtacctcg agagatctcg gtcgactcat ctaatggcac
       61 agacaacgat gacgacgatg gccgtgagga tggtgaagaa cagggagctg atgttcaggg
      121 ccttggcggt ggaggcgaag gcctgggccc cagtcgtatc acccaccatc ttcctgtccc
      181 tagacttcac ggagtaggca taggctacga agcccaggca gcagaagttc atgaagagtg
      241 tattgaacag ggaccagacc acatggtcag gcgtggagat ctcaggcatg ttgattgtgg
      301 tggctgtcgc agaagttgag atgtggggtg accccagtac aaccacctct tgctgctcct
      361 taggcatggg aattcgggcc tccatggcca taagagcgta atctggaaca tcgtatgggt
      421 acatggtggg cccgcgggta caattccgca gcttttagag cagaagtaac acttccgtac
      481 aggcctagaa gtaaaggcaa catccactga ggagcagttc tttgatttgc accaccaccg
      541 gatccgggac ctgaaataaa agacaaaaag actaaactta ccagttaact ttctggtttt
      601 tcagttcctc tagtaccgga tcctctagag tccggaggct ggatcggtcc cggtgtcttc
      661 tatggaggtc aaaacagcgt ggatggcgtc tccaggcgat ctgacggttc actaaacgag
      721 ctctgcttat atagacctcc caccgtacac gcctaccgcc catttgcgtc aatggggcgg
      781 agttgttacg acattttgga aagtcccgtt gattttggtg ccaaaacaaa ctcccattga
      841 cgtcaatggg gtggagactt ggaaatcccc gtgagtcaaa ccgctatcca cgcccattga
      901 tgtactgcca aaaccgcatc accatggtaa tagcgatgac taatacgtag atgtactgcc
      961 aagtaggaaa gtcc
//
